These Analysts Revise Their Forecasts On HCA Healthcare Following Q4 Results

HCA Healthcare Inc. HCA reported better-than-expected earnings for its fourth quarter on Friday.

The company posted fourth-quarter revenues of $18.29 billion, up 5.7% year-over-year, slightly above the consensus of $18.23 billion. The hospital chain reported adjusted EPS of $6.22, up from $5.90 a year ago, surpassing the consensus of $6.13.

“We finished 2024 with strong business fundamentals that were consistent with previous quarters,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “The first half of the current decade, which ended in 2024, proved to be another period of long-term growth for the company and resulted in operational improvements across key performance indicators and greater value for our patients, employees and shareholders. These accomplishments are a testament to the incredible work of our teams, and position us well for the future.”

HCA Healthcare forecasts 2025 EPS of $24.05-$25.85 versus a consensus of $24.58, with a sales outlook of $72.8 billion-$75.8 billion versus a consensus of $74.76 billion.

The company expects a 2025 net profit of $5.85 billion-$6.29 billion and adjusted EBITDA of $14.30 billion—$15.10 billion. Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion to $5.2 billion.

HCA Healthcare shares fell 3.8% to close at $313.07 on Friday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

Barclays analyst Andrew Mok maintained HCA Healthcare with an Overweight rating and lowered the price target from $392 to $366.
Cantor Fitzgerald analyst Sarah James reiterated HCA Healthcare with an Overweight rating and maintained a $405 price target.

Considering buying HCA stock? Here’s what analysts think: